CD274 and non-small cell lung carcinoma: conducted a pooled analysis of KEYNOTE-001, KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042, which explored the outcomes of pembrolizumab in PD-L1-positive [tumor proportion score (TPS) ≥ 1%] NSCLC with BM (77).